Skip to main content

In “Does Temporary Generic Competition Have a Lasting Impact on Branded Drug Sales?” Director Dr. David Blackburn and Senior Consultant Dr. Rasmus Jørgensen analyze the performance of branded drugs following the entry and exit of an “at-risk” generic competitor.

The authors cover a diverse set of six pharmaceutical products, each of which was (1) launched “at-risk,” (2) subsequently withdrawn leading to a period of time in which generics were no longer available, and (3) had data available for a sufficient period of time to identify whether or not there was a lasting impact from the temporary generic entry.

These examples provide important insights into the market responses to temporary generic entry and their potential long-term effects, including whether branded drugs can return to their long-term sales and prescriptions trends in the market without the risk of irreparable harm.

Download Publication